Analysts are on the Bearish side about Epizyme, Inc. (NASDAQ:EPZM) this week.

Epizyme, Inc. (NASDAQ:EPZM) Logo
Investors sentiment increased to 2.34 in Q2 2019. Its up 0.60, from 1.74 in 2019Q1. It improved, as 16 investors sold Epizyme, Inc. shares while 19 reduced holdings. 32 funds opened positions while 50 raised stakes. 80.53 million shares or 8.06% more from 74.53 million shares in 2019Q1 were reported.
Ghost Tree Limited Liability Company owns 465,000 shares. Nea Limited Liability Corporation reported 4.38M shares. Whittier has invested 0% in Epizyme, Inc. (NASDAQ:EPZM). Moreover, Voya Inv Management Limited Liability Corp has 0.01% invested in Epizyme, Inc. (NASDAQ:EPZM). Tudor Et Al reported 43,879 shares. Macquarie Group Ltd invested 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Moreover, Bank Of New York Mellon has 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 316,862 shares. Bnp Paribas Arbitrage holds 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM) for 8,439 shares. Jefferies Grp Lc accumulated 40,200 shares or 0% of the stock. Dimensional Fund Advsr Ltd Partnership has 0% invested in Epizyme, Inc. (NASDAQ:EPZM). Texas Treasury Safekeeping Communications holds 0% in Epizyme, Inc. (NASDAQ:EPZM) or 5,287 shares. Vanguard Gru reported 0% stake. Grp Inc One Trading Limited Partnership stated it has 0% of its portfolio in Epizyme, Inc. (NASDAQ:EPZM). Charles Schwab Inv Mngmt Incorporated holds 459,308 shares. Hamilton Lane Limited Co stated it has 24,673 shares or 0.15% of all its holdings.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 2 analysts covering Epizyme (NASDAQ:EPZM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Epizyme has $25 highest and $18 lowest target. $21.50’s average target is 79.77% above currents $11.96 stock price. Epizyme had 3 analyst reports since June 1, 2019 according to SRatingsIntel. Cowen & Co maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Friday, June 21. Cowen & Co has “Buy” rating and $18 target. H.C. Wainwright maintained Epizyme, Inc. (NASDAQ:EPZM) rating on Monday, June 24. H.C. Wainwright has “Buy” rating and $25 target. Below is a list of Epizyme, Inc. (NASDAQ:EPZM) latest ratings and price target changes.

24/06/2019 Broker: H.C. Wainwright Rating: Buy New Target: $25 Maintain
21/06/2019 Broker: Cowen & Co Rating: Buy New Target: $18 Maintain
01/06/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.48% or $0.18 during the last trading session, reaching $11.96. About 1.69 million shares traded or 119.20% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has risen 7.80% since September 13, 2018 and is uptrending. It has outperformed by 7.80% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.09 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: Seekingalpha.com which released: “Epizyme down 3% after filing tazemetostat NDA for epithelioid sarcoma – Seeking Alpha” on July 25, 2019, also Nasdaq.com with their article: “Epizyme (EPZM) Shares Surge More Than 100% YTD: Here’s Why? – Nasdaq” published on May 28, 2019, Seekingalpha.com published: “Epizyme prices equity offerings; shares down 4% premarket – Seeking Alpha” on March 07, 2019. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: Seekingalpha.com and their article: “Epizyme beats Q1 consensus – Seeking Alpha” published on May 06, 2019 as well as Streetinsider.com‘s news article titled: “Epizyme (EPZM) Announces Grant Bogle and Victoria Richon, Ph.D to Board; Beth Seidenberg, MD to Step Down – StreetInsider.com” with publication date: September 04, 2019.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.